2021
Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates
Hsiang M, Chobrutskiy BI, Diaz M, Huda TI, Creadore S, Zaman S, Cios KJ, Gozlan EC, Blanck G. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Translational Oncology 2021, 14: 101069. PMID: 33780706, PMCID: PMC8039726, DOI: 10.1016/j.tranon.2021.101069.Peer-Reviewed Original ResearchT cell receptor alpha geneAmino acidsT cell receptorChemical complementarityV-J recombinationMutant amino acidsThe Cancer Genome Atlas (TCGA) databaseCancer Genome Atlas (TCGA) databaseCancer mutantsBioinformatics approachAlpha geneReceptor alpha geneImmune receptorsComplement genesAtlas databaseMutantsPeptide sequencesSpecific interactionsGenesII bindingLRP2Region 3 sequencesUterine cancerProtein bindingBinding
2019
An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia
Diviney A, Chobrutskiy BI, Zaman S, Blanck G. An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell International 2019, 19: 73. PMID: 30962767, PMCID: PMC6438000, DOI: 10.1186/s12935-019-0790-5.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaOlder diagnostic ageDiagnostic agePediatric neuroblastomaLymphoblastic leukemiaPrevalent pediatric cancerCancer survival ratesAge of diagnosisYounger patientsSurvival differencesPediatric cancerHigh levelsPatientsNeuroblastomaSurvival rateGene expression markersAgeExpression markersLeukemiaSurvival metricsBiomarker identificationLevelsCancerDiseaseGenes
2018
MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma
Zaman S, Chobrutskiy BI, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle 2018, 17: 2474-2483. PMID: 30394813, PMCID: PMC6342068, DOI: 10.1080/15384101.2018.1542898.Peer-Reviewed Original ResearchConceptsMAPT expressionGene expressionProliferation-effector genesHuman Genome OrganizationContext of tauopathyH2A histone familyCaspase-9 genesOvarian cancerPediatric neuroblastomaGenome organizationCaspase-3 geneCancer Genome AtlasHistone familyKaplan-Meier survival curvesProtein geneTransactive response DNA binding protein 43Neuronal degenerative diseasesType 1 geneDNA binding protein 43Expression of apoptosisAmyloid precursor protein geneGenesPrecursor protein geneAmyotrophic lateral sclerosisNeuronal cells